As of May 22
| +0.07 / +0.83%|
The 2 analysts offering 12-month price forecasts for Imprimis Pharmaceuticals Inc have a median target of 12.50, with a high estimate of 13.00 and a low estimate of 12.00. The median estimate represents a +47.06% increase from the last price of 8.50.
The current consensus among 2 polled investment analysts is to Buy stock in Imprimis Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.